Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora has agreed to merge its animal health business, MWI Animal Health, with Covetrus, valuing MWI at an enterprise value of $3.5 billion. At closing, Cencora will receive $1.25 billion in cash plus equity in the combined parent, including $800 million of perpetual preferred units and $1.45 billion of common units.
After the merger closes and regulatory and other customary conditions are met, Cencora expects to own about 34.3% of the combined CVET TopCo, LP as a non‑controlling shareholder. Cencora notes that its fiscal 2026 guidance does not assume the transaction will close within its 2026 fiscal year.
Cencora, Inc. completed a public offering of $3.0 billion of unsecured senior notes across five tranches, with coupons ranging from 3.950% to 5.650% and maturities from 2029 to 2056. The notes are issued under a long-standing indenture with U.S. Bank Trust Company as trustee and include standard covenants on liens, sale-leasebacks, and mergers, plus customary events of default that can accelerate repayment.
Cencora intends to use the net proceeds to repay amounts outstanding under its 364-Day Term Credit Agreement, which helped fund its acquisition of OneOncology, and to use any remaining funds for general corporate purposes. This transaction replaces short-term acquisition financing with longer-term fixed-rate debt.
Cencora, Inc. is issuing $3.0 billion of unsecured senior notes in five tranches maturing between 2029 and 2056, with fixed coupons ranging from 3.950% to 5.650%. Interest will be paid semi‑annually, and the notes rank equally with Cencora’s other unsecured, unsubordinated debt and are structurally subordinated to subsidiary liabilities.
Cencora expects net proceeds of about $2.98 billion, which it intends to use to repay in full its $3.0 billion 364‑Day Term Loan Facility used to help fund the approximately $4.6 billion acquisition of OneOncology, with any remaining funds for general corporate purposes.
The notes are redeemable at Cencora’s option (including make‑whole and par call structures) and must be offered for repurchase at 101% of principal plus accrued interest if a defined Change of Control Triggering Event occurs. The securities will be issued in book‑entry form and are not expected to be listed on any exchange.
Cencora, Inc. has priced a multi-tranche senior notes offering totaling $3.0 billion, issuing five series of senior unsecured notes maturing between 2029 and 2056 with coupons ranging from 3.950% to 5.650% in an underwritten registered public offering.
Cencora expects to receive approximately $2.98 billion in net proceeds and plans to use the funds primarily to repay borrowings under its $3.0 billion 364-Day Term Loan Facility used to help finance the OneOncology acquisition, with any remaining proceeds earmarked for general corporate purposes.
Cencora, Inc. plans a multi‑tranche unsecured senior notes offering, with each series paying fixed interest semi‑annually and maturing on different future dates. The notes rank equally with Cencora’s other unsecured, unsubordinated debt and are structurally subordinated to liabilities at subsidiaries.
Cencora intends to use the net proceeds to repay in full borrowings under its $3.0 billion 364‑Day Term Loan Facility, which helped fund the approximately $4.6 billion acquisition of OneOncology, and, if any funds remain, for general corporate purposes. A change of control triggering event requires Cencora to offer to repurchase the notes at 101% of principal plus accrued interest, and the notes are redeemable at Cencora’s option subject to make‑whole and par call terms.
Cencora, Inc. filed an 8-K to revise how it presents past financial results, aligning its 2025 Form 10-K disclosures with a new segment structure: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The change only recasts segment information and does not amend audited financial statements.
Under this structure, fiscal 2025 revenue was $321.3 billion, up 9.3% from 2024, led by U.S. Healthcare Solutions revenue of $285.0 billion, up 9.8%, driven by higher specialty volumes and an additional $7.7 billion of GLP‑1 diabetes and weight‑loss products. Gross profit rose 15.8% to $11.48 billion, and operating income increased 20.8% to $2.63 billion.
Cencora closed the $4.04 billion cash acquisition of Retina Consultants of America in January 2025, plus related contingent consideration, strengthening its retina specialty platform. The company also recorded a $723.9 million goodwill impairment for its PharmaLex reporting unit and reported a 2025 effective tax rate of 30.6%.
Cencora, Inc. reports higher results for the quarter ended December 31, 2025, with revenue of $85.9 billion, up 5.5% year over year, and net income of $566.1 million. Diluted earnings per share were $2.87, compared with $2.50 a year earlier.
Growth was driven mainly by the U.S. Healthcare Solutions segment, where revenue rose 5.0% and gross profit increased 29.5%, helped by the January 2025 acquisition of Retina Consultants of America and strong specialty and GLP‑1 product sales. International Healthcare Solutions revenue grew 9.6%, led by European distribution.
Operating income rose 7.7% to $760.4 million, despite a $249.5 million impairment tied to the U.S. Consulting Services business held for sale. Results benefited from an $86.8 million litigation credit from a derivative lawsuit settlement and a higher LIFO credit of $77.6 million. Cash used in operating activities was $2.3 billion, largely from higher inventories and receivables, while total debt was $7.9 billion. The company also highlights a $4.6 billion cash acquisition of OneOncology completed in February 2026, funded with new debt.
Cencora, Inc. reported quarterly results for the fiscal quarter ended December 31, 2025 via a news release furnished as an exhibit, and is holding a conference call and webcast to discuss these results and related matters.
The company also acquired the majority of the outstanding equity interests it did not previously own in OneOncology, a national oncology-focused physician platform, for total cash consideration of approximately $4.6 billion, funded through new debt financing. OneOncology’s affiliated practices and management retained a minority interest, and OneOncology’s future operating results will be included in Cencora’s U.S. Healthcare Solutions segment.
Cencora, Inc. director Ellen G. Cooper filed an initial ownership report on Form 3 stating that she currently holds no securities of Cencora. The filing confirms her status as a director and formally records that she has no beneficial ownership of the company’s securities at this time.
Cencora, Inc. President & CEO Robert P. Mauch reported an option exercise and share sale. On January 20, 2026, he exercised a non-qualified stock option for 3,763 shares of Cencora common stock at an exercise price of $86.09 per share. On the same date, he sold 5,096 shares of common stock at a price of $354.73 per share. After these transactions, he directly owned 66,726 shares of Cencora common stock and held 3,762 stock options linked to common shares. The option referenced in the filing became exercisable in four equal installments from November 13, 2020 through November 13, 2023.